What is the appropriate treatment regimen for an adult with generalized pustular psoriasis who has developed moon‑facial Cushingoid changes from prolonged oral corticosteroid therapy?

Treatment Regimen for Pustular Psoriasis with Cushingoid Features from Prolonged Steroid Use

Immediately discontinue oral corticosteroids and initiate acitretin as first-line therapy for generalized pustular psoriasis, as systemic retinoids demonstrate rapid and remarkable response in pustular variants while avoiding further immunosuppression and steroid-related complications. 1

Immediate Management Priorities

Discontinue Oral Corticosteroids

• Taper and discontinue systemic corticosteroids immediately, as prolonged use has already caused Cushingoid features (moon facies) and corticosteroids should be used only cautiously in GPP, limited to short-term therapy during severe systemic illness phases 2, 3
• The presence of moon facies indicates significant steroid toxicity requiring urgent cessation to prevent further metabolic and cardiovascular complications

Initiate Acitretin as First-Line Therapy

• Start acitretin 10-50 mg daily (titrate based on tolerability and clinical response, with maximum doses up to 70 mg daily reported) 1
• Acitretin demonstrates 84% improvement rates in pustular psoriasis with rapid and remarkable response, particularly in generalized pustular variants 1
• Critical advantage: Acitretin is NOT immunosuppressive, making it ideal for this patient who needs to avoid further immunosuppression while recovering from steroid complications 1
• The response of pustular psoriasis to systemic retinoids can be quite rapid and remarkable 1

Alternative and Adjunctive Options

Biologic Therapy Considerations

• Infliximab may be considered as monotherapy for pustular or erythrodermic subtypes of moderate-to-severe psoriasis (Strength C recommendation) 1
• Recent evidence suggests infliximab may be first-line in severe acute GPP cases due to rapid onset of action and favorable side-effect profiles compared to oral systemic agents 4
• Spesolimab (IL-36 receptor antagonist) represents the newest targeted therapy, FDA-approved specifically for GPP flares, with demonstrated efficacy in steroid-refractory cases 5, 6, 7
  • Administered as 900 mg IV infusion, can be repeated one week apart for severe flares 5
  • Particularly relevant for this patient given steroid failure and Cushingoid complications 6

Agents to Avoid in This Patient

• Cyclosporine should be avoided due to hypertension risk (contraindicated in patients with hypertension) and this patient likely has steroid-induced hypertension given Cushingoid features 1
• Methotrexate shows 76.2% effectiveness but requires careful consideration given potential hepatotoxicity and the patient's metabolic burden from steroids 3
• Additional systemic corticosteroids are contraindicated given existing Cushingoid toxicity 2, 6

Combination Therapy Strategy

Acitretin Plus Phototherapy

• After 2 weeks of acitretin monotherapy, add narrowband UVB (NB-UVB) phototherapy if response is inadequate 1
• Reduce initial UVB dose by 30-50% for the first week due to acitretin-induced increased susceptibility to UVB erythema, then gradually increase as tolerated 1
• Combination therapy achieves 74% improvement in psoriasis severity versus 42% with acitretin alone 1

Topical Adjuncts

• High-potency corticosteroids with or without vitamin D analogues can augment efficacy when combined with systemic therapy 1
• Topical therapy helps manage residual lesions while systemic agents take effect

Monitoring and Follow-Up

Steroid Withdrawal Monitoring

• Monitor for adrenal insufficiency during corticosteroid taper
• Watch for GPP flare triggered by steroid withdrawal (a known precipitant of GPP flares) 4, 8
• Monitor blood pressure, glucose, and lipids as Cushingoid features resolve

Acitretin-Specific Monitoring

• Baseline and periodic lipid panels and liver function tests
• Pregnancy prevention counseling (teratogenic for 3 years after discontinuation in women of childbearing potential)
• Monitor for mucocutaneous side effects (cheilitis, xerosis)

Clinical Pitfalls to Avoid

• Do not continue or restart systemic corticosteroids even if initial GPP flare worsens during transition—this perpetuates the steroid dependency cycle 2, 6
• Do not delay acitretin initiation waiting for steroid taper completion—start immediately as acitretin is non-immunosuppressive 1
• Do not use cyclosporine as an alternative given likely steroid-induced hypertension 1
• If acitretin fails after adequate trial (3-6 months), escalate to biologic therapy (infliximab or spesolimab) rather than reintroducing steroids 1, 5, 4